PDCD1 and neoplasm: Camrelizumab can bind to PD-1 and block the interaction with PD-L1 to prevent the activation of PD-1 and its downstream signal pathway, and restore immune function by activating the immune response against tumor cells or pathogens mediated by cytotoxic T lymphocytes (CTLs) (24).